|
Günther Frankenne is an Economist who started his professional career at Sandoz AG in 1968. He served as CEO of Wander Pharma and as CEO of Sandoz AG. He was involved in the 3-year merger-process between Ciba-Geigy and Sandoz to form Novartis, where he held the position of Deputy Chairman and has been active until his retirement in 1999. Furthermore, he headed committees at the Bundesverband der Pharmazeutischen Industrie (BPI) and Verband forschender Arzneimittelhersteller (VFA). Currently Günther Frankenne is a Board member of Forum Medizin Technik und Pharma (initiated by the Ministry of Economic Affairs in Bavaria) and acts as consultant for Health Care companies. In his capacity he holds positions in various Supervisory Boards. | 